NASDAQ:ECYT - Endocyte Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $16.62 -0.71 (-4.10 %) (As of 07/23/2018 11:30 AM ET)Previous Close$17.34Today's Range$16.59 - $17.3452-Week Range$1.17 - $17.70Volume10,542 shsAverage Volume1.07 million shsMarket Capitalization$1.20 billionP/E Ratio-16.93Dividend YieldN/ABeta0.56 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana. Receive ECYT News and Ratings via Email Sign-up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:ECYT CUSIP29269A10 Webwww.endocyte.com Phone765-463-7175 Debt Debt-to-Equity RatioN/A Current Ratio37.86 Quick Ratio37.86 Price-To-Earnings Trailing P/E Ratio-16.93 Forward P/E Ratio-23.74 P/E GrowthN/A Sales & Book Value Annual Sales$70,000.00 Price / Sales16,501.29 Cash FlowN/A Price / CashN/A Book Value$1.99 per share Price / Book8.35 Profitability EPS (Most Recent Fiscal Year)($1.00) Net Income$-55,060,000.00 Net Margins-70,510.81% Return on Equity-34.20% Return on Assets-32.76% Miscellaneous Employees44 Outstanding Shares69,500,000Market Cap$1,204.46 Endocyte (NASDAQ:ECYT) Frequently Asked Questions What is Endocyte's stock symbol? Endocyte trades on the NASDAQ under the ticker symbol "ECYT." How were Endocyte's earnings last quarter? Endocyte, Inc. (NASDAQ:ECYT) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.02 million for the quarter. Endocyte had a negative return on equity of 34.20% and a negative net margin of 70,510.81%. View Endocyte's Earnings History. What price target have analysts set for ECYT? 4 equities research analysts have issued 12 month target prices for Endocyte's shares. Their predictions range from $21.00 to $21.00. On average, they anticipate Endocyte's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price. View Analyst Ratings for Endocyte. What is the consensus analysts' recommendation for Endocyte? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endocyte in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Endocyte? Endocyte saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 8,046,703 shares, an increase of 125.7% from the June 15th total of 3,565,788 shares. Based on an average daily trading volume, of 2,063,456 shares, the days-to-cover ratio is presently 3.9 days. Currently, 14.4% of the shares of the stock are sold short. View Endocyte's Current Options Chain. Who are some of Endocyte's key competitors? Some companies that are related to Endocyte include HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals PLC- (GWPH), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec (EVTCY), The Medicines (MDCO), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), Supernus Pharmaceuticals (SUPN) and Heron Therapeutics (HRTX). Who are Endocyte's key executives? Endocyte's management team includes the folowing people: Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)Mr. Michael T. Andriole, Chief Financial Officer (Age 45)Ms. Katherine K. Parker, VP of HR (Age 53)Dr. Alison A. Armour, Chief Medical Officer (Age 54)Dr. Christopher P. Leamon Ph.D., VP of R&D (Age 52) Has Endocyte been receiving favorable news coverage? Media headlines about ECYT stock have been trending somewhat positive recently, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endocyte earned a media sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.88 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are Endocyte's major shareholders? Endocyte's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Street Advisors Inc. NC (0.03%). Company insiders that own Endocyte stock include Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte. Which institutional investors are buying Endocyte stock? ECYT stock was bought by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC. View Insider Buying and Selling for Endocyte. How do I buy shares of Endocyte? Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Endocyte's stock price today? One share of ECYT stock can currently be purchased for approximately $16.62. How big of a company is Endocyte? Endocyte has a market capitalization of $1.20 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe. How can I contact Endocyte? Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175. MarketBeat Community Rating for Endocyte (NASDAQ ECYT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 273 (Vote Outperform)Underperform Votes: 203 (Vote Underperform)Total Votes: 476MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?